MedTrace Logo

Perinatal Covid-19 Infection, NO Pathway, and Minipuberty

NCT04952870 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-05-20

No results posted yet for this study

Summary

Some evidence exists that SARS-COV-2 may infect pituitary axis, and therefore may alter hypothalamic function. Whether perinatal COVID-19 is associated with alterations in the maturation of the Hypothalamic-Pituitary-Gonadal (HPG) axis, and specifically with its transient activation occurring during infancy, namely minipuberty, is a major concern. Among the various pathogenic features related to COVID-19, altered minipuberty could be a key factor underlying many multimorbidities later in life, suggesting that they could involve a common causative mechanism that occurs within this short and critical period of time following birth. Altered minipuberty together with NO deficiency seem to be key factors underlying many of these multimorbidities, suggesting that they involve a common causative mechanism that occurs within this short and critical period of time following birth

Conditions

Interventions

OTHER

Inhaled NO

Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure

OTHER

routine care

Patients treated for respiratory failure

Sponsors & Collaborators

Principal Investigators

  • Laurent STORME, MD,PhD · University Hospital, Lille

Eligibility

Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • France
  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952870 on ClinicalTrials.gov